Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL751715 | 1.00 | ALDH1A1 (0.39) | ALDH1A1CYP2C19 | |
| SCHEMBL754899 | 1.00 | ALDH1A1 (0.39) | ALDH1A1CYP2C19 | |
| SCHEMBL2575275 | 0.78 | ALDH1A1 (0.50) | ALDH1A1CYP2C19 | |
| SCHEMBL20919078 | 0.78 | NR1H2 (0.30) | ALDH1A1CYP2C19 | |
| SCHEMBL18098188 | 0.78 | ALDH1A1 (0.30) | ALDH1A1CYP2C19 | |
| SCHEMBL898973 | 0.76 | ALDH1A1 (0.41) | ALDH1A1CYP2C19 | |
| SCHEMBL6305976 | 0.76 | — | — | |
| SCHEMBL12146092 | 0.75 | PDE2A (0.32) | — | |
| SCHEMBL12364516 | 0.75 | — | — | |
| SCHEMBL1372560 | 0.75 | PDE2A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| WO-2024130341-A1 | BENZIMIDAZOLE DERIVATIVES FOR THE MODULATION OF STING | Aculeus Therapeutics Pty Ltd (AU) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024112830-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024086814-A2 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-4289822-A2 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230373937-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230348468-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-11-02 | — | — | US | disclosed |
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | CELLUMEN INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | CELLUMEN INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | MERCK FROSST CANADA LTD. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | MERCK FROSST CANADA LTD. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2009-03-19 | — | — | US | disclosed |
| US-7442716-B2 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-7442716-B2 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. | 2008-08-28 | — | — | US | disclosed |
| US-20070208017-A1 | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2007-09-06 | — | — | US | disclosed |
| US-20070208017-A1 | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348468-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR9, TLR1 | ALDH1A1 1800/4885CYP2C19 3602/4885 |
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | GSTO1, PTGS1, PTGES | ALDH1A1 78/4885CYP2C19 388/4885 |
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | PTGES, PTGS1, PTGES2 | ALDH1A1 158/4885CYP2C19 27/4885 |
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | ALDH1A1 2597/4885CYP2C19 2043/4885 |
| US-20070208017-A1 | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | PTGS1, PTGES, PTGES2 | ALDH1A1 165/4885CYP2C19 24/4885 |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | IRAK4, FLT3, IRAK2 | ALDH1A1 3673/4885CYP2C19 1570/4885 |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | CNR1, CNR2, FAAH | ALDH1A1 3086/4885CYP2C19 455/4885 |
| US-20230373937-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | ALDH1A1 3655/4885CYP2C19 4861/4885 |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | PTGS1, PTGES, PTGES2 | ALDH1A1 165/4885CYP2C19 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.